Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 May;20(4):931-937.
doi: 10.1007/s12015-024-10705-7. Epub 2024 Mar 1.

Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jinlv Qin  1 , Guizuo Wang  2 , Dong Han  3
Affiliations
Meta-Analysis

Mesenchymal Stem Cells on Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jinlv Qin et al. Stem Cell Rev Rep. 2024 May.

Abstract

Background: The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This meta-analysis aimed to determine the efficacy of mesenchymal stem cells (MSCs) on mortality in patients with COVID-19.

Methods: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of COVID-19 with MSCs, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs).

Results: Seventeen RCTs (enrolling 1019 participants) met the inclusion criteria. MSCs showed significant effect on 28-day mortality (RR 0.76, 95% CI 0.62 to 0.93; P = 0.008). There was no statistically significant difference in 60-day mortality (RR 0.87, 95% CI 0.70 to 1.09; P = 0.22), and 90-day mortality (RR 0.91, 95% CI 0.72 to 1.15; P = 0.44) between the two groups.

Conclusions: MSCs significantly reduced 28-day mortality in patients with COVID-19. The long-term effect of MSCs on mortality require further study.

Keywords: COVID-19; MSCs; Meta-analysis; Mortality.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ren, Y., Wang, G., & Han, D. (2023). Statins in hospitalized COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Journal of Medical Virology, 95, e28823. - PubMed - DOI
    1. Memish, Z. A., Faqihi, F., Alharthy, A., Alqahtani, S. A., & Karakitsos, D. (2021). Plasma exchange in the treatment of complex COVID-19-related critical illness: Controversies and perspectives. International Journal of Antimicrobial Agents, 57, 106273. - PubMed - DOI
    1. Cegolon, L., Javanbakht, M., & Mastrangelo, G. (2020). Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents. International Journal of Hygiene and Environmental Health, 230, 113605. - PubMed - PMC - DOI
    1. Osuchowski, M. F., Winkler, M. S., Skirecki, T., Cajander, S., Shankar-Hari, M., Lachmann, G., et al. (2021). The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. The Lancet Respiratory Medicine, 9, 622–642. - PubMed - PMC - DOI
    1. Zhang, Z., Shao, S., Liu, X., & Tong, Z. (2023). Effect and safety of mesenchymal stem cells for patients with COVID-19: Systematic review and meta-analysis with trial sequential analysis. Journal of Medical Virology, 95, e28702. - PubMed - DOI

LinkOut - more resources